Novartis AG (NVS)

86.28
0.25 0.29
NYSE : Health Technology
Prev Close 86.53
Open 86.29
Day Low/High 85.85 / 86.63
52 Wk Low/High 74.97 / 96.31
Volume 1.42M
Avg Volume 1.87M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 218.48B
EPS 5.50
P/E Ratio 16.66
Div & Yield 1.84 (2.12%)
Dow Sets New Record After Smashing Through 20,000 Milestone

Dow Sets New Record After Smashing Through 20,000 Milestone

It finally did it. The Dow Jones Industrial Average smashed through 20,000 after hemming and hawing over the milestone.

Dow Posts Solid Gains After Crossing the 20,000 Milestone

Dow Posts Solid Gains After Crossing the 20,000 Milestone

After slaying its 20,000 milestone Wednesday morning, the Dow Jones Industrial Average extends gains through the afternoon to make a play for 20,100.

What Next as Dow Breaks Through Historic Milestone?

What Next as Dow Breaks Through Historic Milestone?

The Dow Jones Industrial Average finally pushes past the 20,000 milestone after teetering close to that level weeks earlier.

Positive Earnings Are Setting Up the Dow for Its Push to 20,000

Positive Earnings Are Setting Up the Dow for Its Push to 20,000

A series of positive earnings on Wednesday morning set the Dow Jones Industrial Average up to close in on its 20,000 milestone.

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Reports from DuPont and Alibaba looked promising for the markets on Wednesday.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures rise Wednesday and European stocks book solid gains as corporate earnings in the U.S. drive Wall Street higher.

News Out of Europe: Intesa Confirms Potential Bid for Generali

News Out of Europe: Intesa Confirms Potential Bid for Generali

News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.

European Stocks Book Solid Gains as Earnings, Deal Speculation Boost Sentiment

European Stocks Book Solid Gains as Earnings, Deal Speculation Boost Sentiment

European stocks notched solid gains Wednesday as global equity investors build on a strong U.S. corporate earnings season, European deal speculation and encouraging economic data from Japan.

Novartis Misses Fourth-Quarter Earnings Estimate, Mulls Alcon Spinoff

Novartis Misses Fourth-Quarter Earnings Estimate, Mulls Alcon Spinoff

Novartis missed analysts expectations with its fourth quarter earnings but launched a $5 billion share buyback program and said it may sell its Alcon eye care unit.

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

Regulators say company squelched competing drug for infant seizures.

Mallinkrodt Shares Tank Despite $100 Million FTC Deal

Mallinkrodt Shares Tank Despite $100 Million FTC Deal

Drugmaker faced antitrust charges over 2013 Synacthen purchase.

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation

Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

As part of the agreement, Ionis and Akcea are eligible to receive $225 million in near-term payments.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

These 5 Health Care Stocks Are Breaking Out This Christmas

These 5 Health Care Stocks Are Breaking Out This Christmas

The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.

'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It

'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It

Jim Cramer says he's still 'a believer' in KKR and Opko.

Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal

Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal

Stocks kept rallying right through and after this rate hike, says Jim Cramer.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Ophthotech Plunges on Eye-Drug-Study Failure

Ophthotech Plunges on Eye-Drug-Study Failure

Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

TheStreet Quant Rating: A- (Buy)